Advanced cutaneous SCC
With Todd Schlesinger, MD Pembrolizumab extension provides preferred option The July approval of pembrolizumab (Keytruda, Merck) for locally advanced cutaneous squamous cell carcinoma (laCSCC) not curable by surgery or radiation is helping to raise the standard of care for patients who previously had scant alternatives. “Where there was previously no standardized management approach to these […]